Podcasts about part b

Pastor Skip asks you to consider how your attitude can ruin your blessings. Discover why how you handle what you have matters more than how much you make.

Think biblical teaching is just for pastors and missionaries? Pastor Mike Fabarez reveals why every believer is called to study and share God's word. From Paul's example in Acts to insights from Romans and Daniel, we'll realize how ordinary Christians can turn others toward righteousness through biblical truth.

Toni answers these questions: Does Medicare provide dental coverage; does Medicare provide coverage for eye glasses? What's NOT covered by Medicare Part A and Part B? Toni addresses these questions and more on this episode of Medicare Moments. Need more information? Take advantage of Toni's brand new video series now a available at www.tonisays.com Remember - with Medicare it's what you don't know that will hurt you! There's so much good information in this podcast, please be sure to share this podcast with your friends! Recognized by feedspot.com as one of the best Medicare Podcasts in the nation! Write Toni - info@tonisays.com. Toni's book is available at www.seniorresource.com and www.tonisays.com You can call Toni at 832-519-8664 Toni welcomes all Medicare questions. Toni now offers informative Medicare Webinars for all of your Medicare needs at www.Tonisays.com You can find Medicare Moments wherever you find your favorite podcasts, such as: Apple: https://apple.co/44MoguGSpotify: https://open.spotify.com/show/7c82BS4hb145GiVYfnIRsoAmazon Music: https://music.amazon.com/podcasts/884c1f46-9905-4b29-a97a-1a164c97546b/medicare-moments?refMarker=null Toni's new book: Maze of Medicare is now available at www.tonisays.com Combining Scripture with Medicare, it is the only book of its kind. Toni's columns appear weekly in about 100 newspapers across America. If you would like Toni's column to appear in your local paper, or if you would like Toni to speak at an event - contact Toni King at 832-519-8664 Thank you for listening and be sure to tell your friends about Medicare Moments! Blessings!See omnystudio.com/listener for privacy information.

Who's really in charge of your life? Join us as Nate Heitzig challenges you to surrender control—and discover that God's plans for you are better than your own.

God cares for His people very much, so He is very specific about what they should and should not do. There were many bad influences that God did not want them to pick up from the pagan nations that they were coming into contact with.

On BDO's latest Private Equity PErspectives podcast episode, Host Todd Kinney is once again joined by Jason Frank, President and Chief Compliance Officer at BDO Capital Advisors, and Jamie Austin, Global Private Equity Leader and Partner at BDO UK. Together, they explore the findings from BDO's 2025 PE Survey, including:Who PE firms currently view as the top competition for dealmakingEffective value creation strategies amid ongoing extended holding periodsThe top factors PE predict could accelerate M&A activity in 2025Investment banking products and services within the United States are offered exclusively through BDO Capital Advisors, LLC, a separate legal entity and affiliated company of BDO USA, P.C., a Virginia professional corporation. For more information, visit www.bdocap.com. Certain services may not be available to attest clients under the rules and regulations of public accounting. BDO Capital Advisors, LLC Member FINRA/SIPC.

Real Faith (Part - B)Welcome to the Shan Kikon Audio Podcast & Sermon.Here you will find sermons to instruct, establish, equip, and release you to fulfil your full potential in Christ.

How should believers respond to a dark and broken world? Join us as Nate Heitzig shares why you shouldn't expect light from those still in darkness—and how to respond with grace.

Words can build bridges or burn them down—the difference often lies in timing and audience. Pastor Mike Fabarez continues his practical teaching on biblical communication by highlighting what we should say and when we should say it, showing how proper answers at proper moments become precious gifts.

Holiness in our personal conduct is outlined here. Though most of this is repetitive of what God has already instructed to His people, here God also emphasizes “Be holy because I, the LORD your God, am holy”.

Send us a textEpisode SummaryWhat happens when Medicare is slowly dismantled? In this episode, we unpack the ripple effects of recent federal budget and tax policies—especially the One Big Beautiful Bill—on women's health, insurance costs, and the overall provision of care.From older women losing long-term supports, to mothers pushed out of Medicaid after giving birth, to rural hospitals shutting down, the cuts aren't just numbers on a page. They are lived realities for millions of women across every stage of life.We'll explore:How $500B in Medicare cuts will impact access to doctors, hospitals, and prescription drugsWhy women—especially low-income women, women of color, and older women—bear the greatest burdenThe domino effect on insurance premiums, hospital closures, and family financesReal-world stories of women navigating gaps in coverageWhat policy fixes and grassroots actions are still possibleKey TakeawaysDismantling Medicare isn't repeal—it's stealth budget cuts that reduce reimbursements, shrink benefits, and limit eligibility.Women are disproportionately impacted at every stage of life: from family planning to maternal care to aging.Insurance costs will rise—with projected 2026 increases of 11% for Part B and 6% for Part D.Hospital closures and provider shortages will deepen care deserts, especially in rural areas.Advocacy matters—from calling legislators to supporting community clinics and advocacy groups.Resources & Links MentionedWashington Post – What the GOP's tax bill means for your health careMarketWatch – $500 billion in Medicare cuts could result from Republican tax billInvestopedia – 10 Big Medicare Changes in 2026Support the showThe hashtag for the podcast is #nourishyourflourish. You can also find our firm, The Eudaimonia Center on the following social media outlets:Facebook: The Eudaimonia CenterInstagram: theeudaimoniacenterThreads: The Eudaimonia CenterFor more integrative reproductive medicine and women's health information and other valuable resources, make sure to visit our website.Have a question, comment, guest suggestion, or want to share your story? Email us at info@laurenawhite.com

In this episode, Greg Wilkes sits down with fire engineer Andrea White to make Part B practical for builders and developers, so you can design once, build once, and get signed off first time.

Does God really run to meet you when you turn to Him? Listen as Pastor Skip shares the heart behind the story of the prodigal son—and why God welcomes you home with open arms.

Success has a sneaky way of making us forget who deserves the credit. Pastor Mike Fabarez reveals the hidden danger lurking behind prosperity and achievement, showing why gratitude becomes our spiritual lifeline when things are going well.

When people grieve, they usually run the gamut of the emotional spectrum, from denial to bargaining to despair to anger to eventually hope. Mary Magdalene was in hopeless despair as she stood weeping by the grave of Jesus. The resurrected Christ deals tenderly with this woman as he reveals Himself to her and conveys hope for her future. Let's glean some principles for dealing with brokenhearted people.

Jim and Chris discuss listener questions on Social Security timing rules, retroactive benefits for an ex-spouse, investment strategy philosophy, fraternal benefit societies, and Roth conversions.(6:30) The guys address a listener's question about whether applying for Social Security at 70 requires enrolling in Part B or if retroactive filing is an option without losing payments.(16:00) A […] The post Social Security, Risk Philosophy, Fraternal Benefit Societies, Roth Conversions: Q&A #2535 appeared first on The Retirement and IRA Show.

Where does true wisdom begin? Join Pastor Skip as he unpacks the kind of wisdom that flows from God—and how to ask for it with confidence.

This is the outline for acceptable sexual behavior that God gave to Moses for His people. A sensitive subject, but one God deals with because He loves and cares for the people.  Telling them do not do as the Nations do, with their abominable practices.

The healthcare landscape changes dramatically when you hit retirement age, and Medicare—that government program you've been paying into for decades—finally becomes available. But is it really the free healthcare solution many Americans believe it to be? In this illuminating episode, we unpack the reality behind the Medicare system and what it actually costs retirees.Many approaching retirement assume Medicare will eliminate their healthcare expenses, but the truth is far more complex. We break down each component of Medicare—from premium-free Part A (hospital coverage) with its surprising $1,600 per-stay deductible to Part B's monthly premiums of $175 for doctor visits and medical tests. You'll learn why Medicare Part C (Advantage Plans) might seem attractive with added vision and dental benefits but could ultimately restrict your healthcare choices, and why traditional Medicare with a supplement plan offers more comprehensive coverage despite higher upfront costs.The financial reality is sobering: even with Medicare, retirees should budget $6,000-$10,000 per person annually for healthcare expenses. This includes premiums, deductibles, and costs for services Medicare doesn't cover like comprehensive dental, vision, and hearing care. We share practical strategies for managing these expenses, including leveraging HSA accounts from your working years to cover Medicare premiums tax-free, and why coordinating your Social Security start date with Medicare enrollment can simplify premium payments.Don't get caught unprepared by Medicare's complexities. Whether you're approaching retirement or helping aging parents navigate their healthcare options, this episode provides the clear, straightforward guidance you need to make informed decisions. And remember to review your coverage during the annual open enrollment period from October through December 7th—even if you're satisfied with your current plan, as benefits and networks frequently change. Envision Financial Planning. 5100 Poplar Avenue, Suite 2428, Memphis, TN 38137. (901) 422-7526. This communication is strictly intended for individuals residing in the United States. Advisory Services offered through Envision Financial Planning, a Registered Investment Adviser.

Host Davide Soldato and guest Dr. John K. Lin discuss the JCO article "Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-For-Service Beneficiaries with Metastatic Breast, Colorectal, Lung, and Prostate Cancer." TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Dr. Davide Soldato: Hello, and welcome to JCO After Hours, the podcast where we sit down with authors of the latest articles published in the Journal of Clinical Oncology. I'm your host, Dr. Davide Soldato, a medical oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by Dr. Lin, assistant professor in the Department of Health Services Research at the University of Texas MD Anderson Cancer Center. Dr. Lin and I will be discussing the article titled, "Racial and Ethnic Disparities Along the Treatment Cascade Among  Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancer." Thank you for speaking with us, Dr. Lin. Dr. Lin: Thank you so much for having me. I appreciate it. Dr. Davide Soldato: So, just to start, to frame a little bit the study, I just wanted to ask you what prompted you and your team to look specifically at this question - so, racial and ethnic disparities within this specific population? And related to this question, I just wanted to ask how this work is different or builds on previous work that has been done on this research topic. Dr. Lin: Yeah, absolutely. Part of the impetus for this study was the observation that despite people who are black or Hispanic having equivalent health insurance status - they all have  Medicare Fee-for-Service - we've known that treatment and survival differences and disparities have persisted over time for patients with metastatic breast, colorectal, lung, and prostate cancer. And so, the question that we had was, "Why is this happening, and what can we do about it?" One of the reasons why eliminating racial and ethnic disparities in survival among Medicare beneficiaries with metastatic cancer has been elusive is because these disparities are occurring along a lot of dimensions. Whether or not it's because the patient presented late and has very extensive metastatic cancer; whether or not the patient has had a difficult time even seeing an oncologist; whether or not the patient has had a difficult time starting on any systemic therapy; or maybe it's because the patient has had a difficult time getting guideline-concordant systemic therapy because, more recently, these treatments have become so expensive. Disparities, we know, are occurring along all of these different facets and areas of the treatment cascade. Understanding which one of these is the most important is the key to helping us alleviate these disparities. And so, one of our goals was to evaluate disparities along the entire treatment cascade to try to identify which disparities are most important. Dr. Davide Soldato: Thank you very much. That was very clear. So, basically, one of the most important parts of the research that you have performed is really focusing on the entire treatment cascade. So, basically, starting from the moment of diagnosis up to the moment where there was the first line of treatment, if this line of treatment was given to the patient. So, I was wondering a little bit, because for this type of analysis, you used the SEER-Medicare linked database. So, can you tell us a little bit which was the period of time that you selected for the analysis? Why do you think that that was the most appropriate time to look at this specific question? And whether you feel like there is any potential limitation in using this type of database and how you handled this type of limitations? Dr. Lin: Yeah, absolutely. It's a great question. And I want to back up a little bit because I want to talk about the entire treatment cascade because I think that this is really important for our research and for future research. We weren't the first people to look at along the treatment cascade for a disease. Actually, this idea of looking along the treatment cascade was pioneered by HIV researchers and has been used for over a decade by people who study HIV. And there are a lot of parallels between HIV and cancer. One of them is that with HIV, there are so many areas along that entire treatment cascade that have to go right for somebody's treatment to go well. Patients have to be diagnosed early, they have to be given the right type of antiretrovirals, they have to be adherent to those antiretrovirals. And if you have a breakdown in any one of those areas, you're going to have disparities in care for these HIV patients. And so, HIV researchers have known this for a long time, and this has been a big cornerstone in the success of getting people with HIV the treatment that they need. And I think that this has a lot of parallels with cancer as well. And so, I am hoping that this study can serve as a model for future research to look along the entire treatment cascade for cancer because cancer is, similarly, one of these areas that requires multidisciplinary, complex medical care. And understanding where it is breaking down, I think, is crucial to us figuring out how we can reduce disparities. But for your question about the SEER-Medicare linked database, so we looked between 2016 and 2019. That was the most recent data that was available to us. And one of the reasons why we were excited to look at this is because there were some new treatments that were just released and FDA-approved around 2018, which we were able to study. And this included immunotherapy for non–small cell lung cancer, and then it also included androgen receptor pathway inhibitors, the second-generation ones, for prostate cancer. And the reason why this is important is because for some time, as we have developed these new therapies, there's been a lot of concern that there have been disparities in access to these novel therapies because of how expensive they are, particularly for the Medicare population. And so one of the reasons why we looked specifically at this time period was to understand whether or not, in more recent years, these novel therapies, people are having increasing disparities in them and whether or not increasing disparities in these more expensive, newer therapies is contributing to disparities in mortality. That being said, obviously, we're in 2025 and these data are by now six years old, and so there are additional therapies that are now available that weren't available in the past. But I think that, that being said, at least it's sort of a starting point for some of the more important therapies that have been introduced, at least for non–small cell lung cancer and prostate cancer. And the database, SEER-Medicare, is helpful because it uses the population cancer registry, which is the SEER registry cancer registry, linked to Medicare claims. So, any type of medical care that's billed through Medicare, which is going to basically be all of the medical care that these patients receive, for the most part, we're going to be able to see it. And so, I think that this is a really powerful database which has been used in a lot of research to understand what kind of care is being received that has been billed through Medicare. So, one of the limitations with this database is if there is care that's received that was not billed through Medicare, we're not going to be able to see that. And this does not happen probably that frequently, particularly because most patients who have insurance are going to be receiving care through insurance. However, we may see it for some of the oral Part D drugs. Some of those drugs are so expensive that patients cannot pay for the coinsurance during that time. And it's possible that some of those drugs patients were getting for free through the manufacturer. We potentially missed some of that. Dr. Davide Soldato: So, going a little bit into the results, I think that these are very, very interesting. And probably the most striking one is that when we look at the receipt of any type of treatment for metastatic breast, colorectal, prostate, and lung cancer - and specifically when we look at guideline-directed first-line treatments - you observed striking differences. So, I just wanted you to guide us a little bit through the results and tell us a little bit which of the numbers surprised you the most. Dr. Lin: So, what we were expecting is to see large disparities in receiving what we called guideline-directed systemic therapy. And guideline-directed systemic therapy during this time kind of depended on the cancer. So, we thought that we were going to see large disparities in guideline-directed therapy because these were the more novel therapies that were approved, and thus they were going to be the more expensive therapies. And so, what this meant was for colorectal cancer, this was going to be any 5-FU–based therapy. For lung cancer, this was going to be any checkpoint inhibitor–based therapy. For prostate cancer, this was going to be any ARPI, so this was going to be things like abiraterone or enzalutamide. And for breast cancer, this was going to be CDK4 and 6 TKIs plus any aromatase inhibitor. And so, for instance, for breast, prostate, and lung cancer, these were going to be including more expensive therapies. And so, what we expected to see was large disparities in receiving some of these more expensive, novel therapies. And we thought we were going to see fewer disparities in receiving some of the cheaper therapies, such as aromatase inhibitors, 5-FU, older platinum chemotherapies for lung cancer, and ADT for prostate cancer. We were shocked to find that we saw large racial and ethnic disparities in seeing some of the older, cheaper chemotherapies and hormonal therapies. So for instance, for breast cancer, 59% of black patients received systemic therapy, whereas 68% of white patients received systemic therapy. For colorectal, only 23% of black patients received any systemic therapy versus 34% of white patients. For lung, only 26% of black patients received any therapy, whereas 39% of white patients did. And for prostate, only 56% of black patients received any systemic therapy versus 77% of white patients. And so, we were pretty shocked by how large the disparities were in receiving these cheap, easy-to-access systemic therapies. Dr. Davide Soldato: Thank you very much. So, I just wanted to go a little bit deeper in the results because, as you said, there were striking differences even when we looked at very old and also cheap treatments that, for the majority of the patients that were included inside of your study, were actually basically available for a very small price to these patients who had the eligibility for Medicare or Medicaid. And I think that one of the very interesting parts of the research was actually the attention that you had at looking how much of these disparities could be explained by several factors. And actually, one of the most interesting results is that you observed that low-income subsidy status was actually a big determinant of these disparities in terms of treatment. So, I just wanted to guide us a little bit through these results and then just your opinion about how these results should be interpreted by policymakers. Dr. Lin: Yeah, absolutely. I'm going to explain a little bit about what low-income subsidy status is and dual-eligibility status. Some of the listeners may not know what low-income subsidy status or dual-eligibility status is. Low-income subsidy status is part of Medicare Part D. Medicare Part D is an insurance benefit that allows patients to receive oral drugs. So these are drugs that are dispensed through the pharmacy, such as the CDK4/6 inhibitors, as well as second-generation ARPIs in our study. For patients who have Medicare Part D and whose income is low enough - falls below a certain federal poverty level threshold - those patients will receive their oral drugs for much cheaper. And this is really important for some of these more novel therapies because for some of these more novel therapies, if you don't have low-income subsidy status, you may be paying thousands of dollars for a single prescription of those drugs. Whereas if you have low-income subsidy status, you may be paying less than $10. And so that difference, greater than $1,000 or $2,000 versus less than $10, one would think that the patient who's paying less than $10 would be much more likely to receive those therapies. So that's low-income subsidy status. Low-income subsidy status, importantly, doesn't apply for infused medications like immunotherapy. But it's important to know that most people with low-income subsidy status - about 88% - are also dual-eligible. What dual-eligible means is that they have both Medicare and Medicaid. Medicare being the insurance that everybody has in our study who's greater than 65. And Medicaid is the state-run but federally subsidized insurance that patients with low incomes have. And so patients who are dual-eligible - and about 87% of those with low-income subsidy status are dual-eligible - those patients have both Medicaid and Medicare, and they basically pay next to nothing for any of their medical care. And that's because Medicare will reimburse most of the medical care and the copays or coinsurance are going to be covered by Medicaid. So Medicaid is going to pick up the rest of the bill. So, most of the patients who have low-income subsidy status who are dual-eligible, these patients pay almost nothing for their medical care - Part B or Part D, any of their drugs. And so, one would expect that if cost were the main determinant of disparities in cancer care, then one would expect that dual-eligibles, most of them would be receiving treatment because they're facing minimal to no costs. What we found is that when we broke down the racial and ethnic disparity by a number of factors - including LIS status/dual eligibility, age, the number of comorbidities, etcetera - what we found was that the LIS or dual-eligibility status explained about 20% to 45% of the disparities that we saw in receiving treatment. And what that means is despite these patients paying next to nothing for their drugs, these are the most likely patients to not be treated for their cancer at all. So they're most likely to basically be diagnosed, survive for two months, see an oncologist, and then never receive any systemic therapy for their cancer. And this is not just chemotherapies for colorectal or lung cancer. This includes cheaper, easier-to-tolerate hormonal therapies that you can just take at home for breast cancer, or you can get every six months for prostate cancer, that people who even have poorer functional status are able to take. However, for whatever reason, these dual-eligible or LIS patients are very unlikely to receive treatment compared to any other patient. The low likelihood of treating this group of patients, that explains a large portion of the racial and ethnic disparities that we see. Dr. Davide Soldato: And one thing that I think is very interesting and might be of potential interest to our listeners is, did you compare survival outcomes in these different settings? And did you observe any significant differences in terms of racial and ethnic disparities once you saw that there was a significant difference when looking at both receipt of any type of treatment and also guideline-directed treatments? Dr. Lin: We saw that there were large disparities in survival by race and ethnicity when you look overall. However, when you just account for the patients who received any systemic therapy at all - not just guideline-directed systemic therapy - those differences in survival essentially disappeared. And so, what that suggests is that if black patients were just as likely to receive any systemic therapy at all as white patients, we would expect that the survival differences that we were seeing would disappear. And this is not even just looking at guideline-directed systemic therapy. This was looking just at systemic therapy alone. And so, while guideline-directed systemic therapy should be a goal, our research suggests that if we are to close the gap in disparities in overall survival among black and white patients, we must first focus on patients just receiving any type of treatment at all. And that should be the very first focus that policymakers, that leaders in ASCO, that health system leaders, that physicians, that we should focus on: just trying to get any type of treatment to our patients who are poorer or black. Dr. Davide Soldato: Thank you very much. And this was not directly related to the research that you performed, but going back to this very point - so, increasing the number of patients that receive any kind of systemic treatment before looking at guideline-directed treatments - what would you feel would be the best way to approach this in order to decrease the disparities? Would you look at interventions such as financial navigation or maybe improving referral pathways or providing maybe more culturally adapted information to the patients? Because in the end, what we see is disparities based on racial and ethnicity. We see that we can reduce these disparities if we get these patients to the treatment. But in the end, what would you feel is the best way to bring patients to these types of treatments? Dr. Lin: I think the most important thing is to understand that these disparities are not primarily happening because of the high cost of cancer treatment. These disparities are happening because of other social vulnerabilities that these patients are facing. And so these vulnerabilities could be a lot of things. It could be mistrust of the medical system. It could be fear of chemotherapy or other treatments. It could be difficulty taking time off of work. It could be any number of things. What we do know is when we've looked at the types of interventions that can help patients receive treatment, navigation is probably the most effective one. And the reason why I think that is because when patients don't receive treatment because of social vulnerability, I sort of look at social vulnerability like links in a chain. Any weakest link is going to result in the patient not receiving treatment. This may be because they have a hard time taking time off of work. This may be because they had a hard time getting transportation to their physician. It may be because they had an interaction with a physician, but that interaction was challenging for the patient. Maybe they mistrusted the physician. Maybe they're worried about the medical system. If any of these things goes wrong, the patient is not going to be treated. The patient navigator is the only person who can spot any of those weak links within the chain and address them. And so, I think that the first thing to do is to get patient navigation systems in place for our vulnerable patients throughout the United States. And this is incredibly important because in Medicare, patient navigation is reimbursable. And so this is not something that's ‘pie in the sky'. This is something that's achievable today. The second thing is that it's really important that we see these vulnerabilities happening for patients who are dual-eligible, who have both Medicare and Medicaid. One of the reasons why this is important is because there has been a lot of research outside of what we've done that has shown vulnerabilities for dual-eligible patients who have Medicare for a number of different diseases. And the reason why is because, although patients are supposed to have the benefits of both Medicare and Medicaid, usually these two insurances do not play nicely together. It creates a huge, bureaucratic, complex mess and maze that most of these patients are unable to navigate. And so many of these patients are unable to actually receive the full reimbursement from both Medicare and Medicaid that they should be getting because those two insurers are not communicating well. And so the second thing is that national cancer organizations need to be supporting policies and legislation that is already being discussed in Congress to revamp the dual-eligible system so that it facilitates these patients getting properly reimbursed for their care from both Medicare and Medicaid and these systems working together well. The third thing is that Medicaid itself has many benefits that can allow patients to receive care, like they have transportation benefits so that patients can get to and from their doctor's appointments with ease. And so I think this will be additionally very, very helpful for patients. The last thing is, you know, it's possible that future innovations such as telemedicine and tele-oncology and cancer care at home can also make it easier for some of these patients who may be working a lot to receive care. But what I would say is that our study should be a call for healthcare delivery researchers to start piloting interventions to be able to help these patients receive systemic therapy. And so what this could look like is trying to get that care navigation and implement that in clinics so that patients can be receiving the care that they need. Dr. Davide Soldato: Thank you very much. That was a very clear perspective on how we can tackle this issue. So, I just wanted to close with a sort of personal question. I was wondering what led you to work specifically in this research field that is very challenging, but I think it's particularly critical in healthcare systems like in the United States. Dr. Lin: Yeah, absolutely. One of the most important things for me as an oncologist and a researcher is being able to know that all patients in the United States - and obviously abroad - who have cancer should be able to receive the kind of care that they deserve. I don't think that patients, because their incomes are lower or because their skin looks a certain color or because they live in rural areas, these shouldn't be determinants of whether or not cancer patients are receiving the care that they need. We can develop and pioneer the very best treatments and breakthroughs in oncology, but if our patients are not receiving them - if only 20% of our patients with colon cancer or lung cancer are receiving any type of systemic therapy, who are black - this is a big problem. But this is something that I think that our system can tackle. We need to get these breakthroughs that we have in oncology to every single cancer patient in America and every single cancer patient in the world. I think this is a goal that all oncologists should have, and I think that this is something that, honestly, is achievable. I think that research is a powerful tool to give us a lens into understanding exactly why it is that certain patients are not getting the care that they deserve. And my goal is to continue to use research to shed light on why our system is not performing the way that we all want it to be. Dr. Davide Soldato: Circling back to your research, actually the manuscript that was published was supported by a Young Investigator Award by the American Society of Clinical Oncology. So, was this the first step of a more broad research, or do you have any further plans to go deeper in this topic? Dr. Lin: Yeah, absolutely. First, I want to thank the ASCO Young Investigator Award for funding this research because I think it's fair to say that this research would not have happened at all without the support of the ASCO YIA. And the fact that ASCO is doing as much as it can to support the future generation of cancer researchers is incredible. And it's a huge resource, and having it come at the time that it did is critical for so many of us. So I think that this is an unbelievable thing that ASCO does and continues to do with all of its partners. For me, yeah, this is definitely a stepping stone to further research.  Medicare Fee-for-Service is only one part of the population. I want to spread this research and extend it to patients who have other types of insurances, look at other types of policies, and also try to conduct some of the cancer care delivery research that's needed to try to pilot some interventions that can resolve this problem. So hopefully this is the first step in a broader series of studies that we can all do collectively to try to eliminate racial and ethnic disparities in cancer care and survival. Dr. Davide Soldato: So, I think that we've come at the end of this podcast. Thank you again, Dr. Lin, for joining us today. Dr. Lin: Thank you so much. It was a pleasure to be a part of this. Dr. Davide Soldato: So, we appreciate you sharing more on your JCO article, "Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancer." If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Learn how your words can become a source of healing instead of harm. Find wisdom as Pastor Nate Heitzig shares how speaking with grace can refresh others—and reflect Christ.

From the paddocks of Warrnambool to the bright lights of the AFL, Jonathan Brown’s story is pure sporting gold. A country lad who grew up tough and humble, Browny became one of the most courageous and dominant forwards the game has ever seen. Premierships, All-Australians, captain of the Lions – he did it all with that trademark mix of grit, bravery and country charm. But Browny’s story doesn’t end when the boots came off. These days, he’s one of the most loved voices in the game, a straight-shooting, sharp-witted commentator and media star with Fox Footy and beyond. In true Browny fashion, this chat is raw, funny and full of heart. It’s the journey of a good country boy who became a legend of the game. *** Follow the Howie Games on Instagram: https://www.instagram.com/thehowiegamespod/ Follow the Howie Games on TikTok: https://www.tiktok.com/@thehowiegames See omnystudio.com/listener for privacy information.

The Scriptures state: “The life of the flesh is in the blood…” Long before science understood it, the Bible called it. All thru the scriptures, blood is held up both in symbolism and in the facts of life that it brings.

Why does God allow trials in the lives of believers? Pastor Mike Fabarez addresses this crucial question, revealing how divine testing prepares us for future challenges. We'll continue examining Paul's snake bite experience on Malta and understand how God builds resilient faith through unexpected difficulties.

Ready to take control of your retirement? Start your Retirement TEAM Action Plan at ARHQ.com or call 419-794-3030 to speak with a retirement planning specialist today! In this conversation, Scott Kirchner discusses the intricacies of Medicare, addressing common questions and misconceptions that seniors often have. He emphasizes the importance of understanding enrollment periods, the differences between Medicare parts, and the potential penalties for late enrollment. Additionally, he highlights overlooked questions that seniors should consider, such as the impact of HSAs and VA benefits on Medicare enrollment. The conversation concludes with details about an upcoming educational workshop aimed at providing further insights into Medicare benefits and changes. About America's Retirement Headquarters: We are dedicated to helping retirees achieve the retirement they deserve. From crafting personalized retirement income strategies to providing a single location for all your retirement solutions, our goal is to guide you every step of the way. Let us help you navigate the complexities of retirement, so you can enjoy financial confidence and peace of mind. Visit Us: 1700 Woodlands Drive, Maumee, OH 43537 Call Us: 419-794-3030 Learn More: ARHQ.com See omnystudio.com/listener for privacy information.

Why does the enemy target spiritual leaders? Listen as Skip's son, Pastor Nate Heitzig, explains how attacks on pastors impact the whole church—and why your prayers matter more than you think.

Send us a textWhat matters more, holding tightly to your rights or laying them down for the sake of others? The Apostle Paul's letter to the Corinthians challenges us to rethink Christian freedom, self-control, and what it really means to live for the gospel.HOME | PLAN YOUR VISIT | BLOG | DIGITAL BULLETIN

Once a year on the Day of Atonement, the High Priest would enter the “Holy of Holies” and offer the blood of the sacrifice to God in order to cover the sins of the people. Jesus atonement on the cross removed our sins once and forever. He is our substitute for the sin-debt that we […]

What does dead faith really look like? Listen as Pastor Skip paints a vivid picture of belief with no action—and why living faith changes everything.

When everything around you seems to be falling apart, what keeps you anchored? Pastor Mike Fabarez reveals three specific promises that can sustain any believer during life's darkest storms. From complete forgiveness to resurrection hope to guaranteed joy, we'll examine God's "precious and very great promises."

God instructs Moses and Aaron on what to tell the people about keeping themselves clean of contamination from bodily fluids. The New Testament church can draw many valuable spiritual lessons from these texts.  

Can someone know all the right things about God—and still be lost? Find clarity as Pastor Skip shares how saving faith moves from information to transformation.

God, in His abundant mercy, provided a way for the cleansed leper to be brought back in to society. This process was to be administered by the priests. Moses was also given instructions on how to treat a domicile that was infected with a leprous plague.  

There was a lot of confusion happening on the first Easter morning. The resurrection had happened but it was neither expected nor accepted by all at first. Mary Magdalene ran to tell the disciples what she saw, and they ran to check out her report. What they saw was compelling evidence of a resurrection, but only one of them really connected all the dots. Let's see why.

Do you ever let bias shape your behavior? Listen as Pastor Skip unpacks the call to love your neighbor—not just in theory, but in practice.

Do you realize how much your Christian presence matters to those around you? Pastor Mike Fabarez reveals the profound impact believers have in their homes, churches, and communities. Through Paul's protective influence on the storm-tossed ship, he demonstrates why your faithfulness creates a sanctifying effect that reaches far beyond yourself, offering believers fresh understanding of their true spiritual influence.

A sequel to the teaching: FINDING GOD'S WILL FOR YOUR LIFE. In this teaching, Pastor teaches on what our life's desire should be. When it comes to the things of God, the time is now. Whatever is not God's will for your life, should never be your desire.

In this chapter, God gives Moses and Aaron instruction on how diseases of the skin are to be dealt with. The priests were assigned the duty of determining whether the situation required further isolation, so that the infection would not spread thru the community.  

Can your relationship with Jesus change how you speak? Find insight as Pastor Skip shares why a real encounter with Christ should shape your words—and your witness.

A State of Origin hero with one hell of a story. From glory to the most infamous press conference in Australian sport. From rock bottom to a man who now inspires thousands. Darius Boyd’s journey is as raw as it is remarkable. Darius opens up about the mentorship that shaped his career – and life – under Wayne Bennett. We revisit that press conference, his struggles behind the scenes despite on-field triumphs, and the turning point that saw him own his story and use it as a strength. It’s the full Darius Boyd story – unfiltered, inspiring, and unforgettable. *** Follow the Howie Games on Instagram: https://www.instagram.com/thehowiegamespod/ Follow the Howie Games on TikTok: https://www.tiktok.com/@thehowiegames See omnystudio.com/listener for privacy information.

What's choking out spiritual growth in your life? Tune in as Pastor Skip shares how God's Word takes root when you clear out the clutter and make space for truth.

Should Christians engage with secular culture, or simply avoid it? Pastor Mike Fabarez tackles this crucial question head-on. Using Paul's concern for unbelieving shipmates during the storm, he reveals why your influence in society matters more than you think. This challenging message examines our responsibility to speak biblical truth into cultural chaos while maintaining both courage and grace.

The son of Australian sporting royalty, Jackson Warne is beginning a new chapter inspired by his legendary dad, Shane Warne. Three years on from his father’s passing, Jackson has stepped behind the microphone to launch Warne’s Way – It's a podcast where he speaks with people from the world of sport and entertainment, unearthing their own stories of THE KING. From late-night Maccas runs to chance encounters at petrol stations, these tales bring Jackson closer to the dad he misses every day. In this very special simulcast, Howie joins Jackson for Episode 1, diving into memories of life with Shane – the fun, the friendship, and the joy he brought to those around him. It’s a heartfelt celebration of one of Australia’s most iconic figures, told through the eyes of his son. Check out Jackson's project wherever you get your podcasts EVERY MONDAY in the Warne's Way Podcast Feed.See omnystudio.com/listener for privacy information.

The LORD thru Moses and Aaron instructs the people what foods are permitted and which foods are forbidden. Instructions for handling “unclean” animals are also given. God wants the Jews to be a distinct people, and by modifying their dietary habits, He is setting them apart from the Nations that are surrounding them.  

What should you do when temptation strikes? Listen in as Pastor Skip offers a practical plan to flee what's harmful and run straight to the goodness of God.

How do you respond when life tests your faith? Tune in as Pastor Skip challenges you to move beyond complaints to embrace trials as God's opportunity to deepen your trust.

You can find an unending supply of books, pamphlets, and articles on discipleship in Christian churches and bookstores. Many of them will be predictably regimented and conventional, giving solid biblical references and calling Christians to ardently follow Christ—all great stuff. But not everyone's spiritual journey is identical. Some disciples are unexpected, and so is their story. Here are two disciples of Jesus who've been in the background and now step forward to care for the body of Christ after His death. Let's allow their story to inspire us.

What do you do when life feels overwhelming and wisdom feels out of reach? Join Pastor Skip as he shares why God welcomes your honest prayers—and how He generously responds when you ask for help.

What if the very things you hate—like trials and temptations—are God's tools to grow you? Learn why those moments might just be your path to maturity.